05:44 PM EDT, 06/03/2024 (MT Newswires) -- Scholar Rock ( SRRK ) late Monday reported "encouraging" data from a phase 1 proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors.

The company said the results showed encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types.

"Analysis of baseline biomarker data in clear cell renal cell carcinoma patients reveals a doubling of the objective response rate highlighting a potential patient selection strategy," the company said.

Safety data from all cohorts in the dose expansion phase showed SRK-181 remained generally well-tolerated when used alongside pembrolizumab, the drugmaker said.

Shares of the company rose over 3% in extended trading.

Price: 9.80, Change: +0.32, Percent Change: +3.38